April 2022 tender notification
Pharmac is pleased to provide the latest tender results.
Download the tender notification [PDF 74 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 May 2022 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|
|
Docusate sodium with sennosides |
Tab 50 mg with sennosides 8 mg; 200 tablet bottle |
$4.20 |
$3.50 |
Laxsol (Aspen) |
1 June 2022 |
1 November 2022 |
|
Losartan potassium with hydrochlorothiazide1 |
Tab 50 mg with hydrochlorothiazide 12.5 mg; 30 tablet blister pack |
$15.25 |
$4.00 |
Arrow-Losartan & Hydrochlorothiazide (Teva) |
1 August 2022 |
1 January 2023 |
|
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender. |
||||||
2. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|
|
Glycerol |
Suppos 4 g; 20 suppository pack |
$9.25 (suppos 3.6 g) |
$10.39 |
Lax-Suppositories Glycerol (AFT) |
1 September 2022 |
1 February 2023 |
PSM suppos 3.6 mg (API Consumer Brands) |
|
Hydrocortisone |
Crm 1%; 30 g OP tube |
$3.70 (per 100 g) |
$1.78 |
Ethics (Multichem) |
1 November 2022 |
1 April 2023 |
Hydrocortisone (PSM) 100g pack size (API Consumer Brands) |
|
Levonorgestrel |
Tab 1.5 mg; 1 tablet blister pack |
$4.95 |
$1.75 |
Levonorgestrel BNM (Boucher) |
1 January 2023 |
1 June 2023 |
Postinor-1 (Bayer) |
|
Metoclopramide hydrochloride |
Inj 5 mg per ml, 2 ml ampoule; 10 ampoule pack |
$9.50 |
$7.00 |
Baxter (Baxter) |
1 July 2022 |
1 December 2022 |
Pfizer (Pfizer) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
DV limit |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|---|
|
Docusate sodium with sennosides |
Tab 50 mg with sennosides 8 mg; 200 tablet bottle |
$4.20 |
$3.50 |
Laxsol (Aspen) |
5% |
1 June 2022 |
1 November 2022 |
|
Losartan potassium with hydrochlorothiazide2 |
Tab 50 mg with hydrochlorothiazide 12.5 mg; 30 tablet blister pack |
$15.25 |
$4.00 |
Arrow-Losartan & Hydrochlorothiazide (Teva) |
5% |
1 August 2022 |
1 January 2023 |
|
2This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2021/22 Invitation To Tender. |
|||||||
4. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|---|
|
Glycerol |
Suppos 4 g; 20 suppository pack |
$9.25 (suppos 3.6 g) |
$10.39 |
Lax-Suppositories Glycerol (AFT) |
5%3 |
1 September 2022 |
1 February 2023 |
PSM suppos 3.6 mg (API Consumer Brands)4 |
|
Hydrocortisone |
Crm 1%; 30 g tube |
$3.70 (per 100 g) |
$1.78 |
Ethics (Multichem) |
5% |
1 November 2022 |
1 April 2023 |
Hydrocortisone (PSM) 100g pack size (API Consumer Brands) |
|
Levonorgestrel |
Tab 1.5 mg; 1 tablet blister pack |
$4.95 |
$1.75 |
Levonorgestrel BNM (Boucher) |
5% |
1 January 2023 |
1 June 2023 |
Postinor-1 (Bayer) |
|
Metoclopramide hydrochloride |
Inj 5 mg per ml, 2 ml ampoule; 10 ampoule pack |
$9.50 |
$7.00 |
Baxter (Baxter) |
5% |
1 July 2022 |
1 December 2022 |
Pfizer (Pfizer) |
|
3The following note will be added to the listing of “Glycerol suppos 4 g” as follows: “Note: DV limit applies to glycerol suppository presentations.” 4The following presentations will also be delisted from 1 February 2023: “Glycerol suppos 1.27 g” and “Glycerol suppos 2.55 g”. |
||||||||
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021.
|
Chemical name |
Line item |
|---|---|
|
Busulfan |
Inj 6 mg per ml |
|
Chlorhexidine with cetrimide |
Irrigation soln 0.015% with cetrimide 0.15%, 500 ml |
|
Chlorpromazine Hydrochloride |
Inj 25 mg per ml, 2 ml ampoule |
|
Chlorpromazine Hydrochloride |
Tab 10 mg |
|
Chlorpromazine Hydrochloride |
Tab 25 mg |
|
Chlorpromazine Hydrochloride |
Tab 100 mg |
|
Ethinyloestradiol with Norethisterone |
Tab 35 mcg with norethisterone 1 mg |
|
Glyceryl trinitrate |
Inj 5 mg per ml, 10 ml ampoule |
|
Hydrocortisone |
Oint 1% (pack size greater than 100 g) |
|
Hydrocortisone |
Oint 1% (pack size 100 g or less) |
|
Hydrocortisone with natamycin and neomycin |
Crm 1% with natamycin 1% and |
|
Lomustine |
Cap 10 mg |
|
Lomustine |
Cap 40 mg |
|
Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate |
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet |
|
Macrogol 3350 with potassium chloride, sodium chloride, sodium sulfate and ascorbic acid [x1 sachet]; and citric acid with magnesium oxide and picosulfate [x2 sachets] |
Powder for oral soln |
|
Paracetamol |
Suppos 25 mg |
|
Paracetamol |
Suppos 50 mg |
|
Paracetamol with codeine |
Tab paracetamol 500 mg with codeine phosphate 15 mg |
|
Pholcodine |
Oral liq 1 mg per ml |
|
Prochlorperazine |
Tab 3 mg buccal |
|
Telmisartan |
Tab 40 mg |
|
Telmisartan |
Tab 80 mg |
|
Telmisartan with hydrochlorothiazide |
Tab 40 mg with hydrochlorothiazide 12.5 mg |
|
Telmisartan with hydrochlorothiazide |
Tab 80 mg with hydrochlorothiazide 12.5 mg |
For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.